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Abstract  
Aims: Detection of early-stage atherosclerosis in type 2 diabetes mellitus (T2DM) 
patients is important for preventing cardiovascular disease. A phased tracking method 
for evaluating arterial wall elasticity sensitively detects early-stage atherosclerosis. 
However, biochemical markers for early-stage atherosclerosis have yet to be 
established. 
Methods: This cross-sectional study enrolled 180 T2DM patients, who were classified 
as not having atherosclerosis according to the carotid intima-media thickness (IMT) 
criteria. We measured serum cystatin C, the estimated glomerular filtration rate (eGFR) 
and urinary albumin-to-creatinine ratio (ACR), and analyzed the associations between 
these markers and arterial wall elasticity (Eθ), IMT and the cardio-ankle velocity index. 
Results: Multiple linear regression analyses revealed that cystatin C was significantly 
associated with Eθ, while neither eGFR nor ACR showed an association. Furthermore, 
among the examined atherosclerotic markers, Eθ was most reliably associated with 
cystatin C. Additionally, the association between cystatin C and Eθ disappeared in the 
low elasticity subgroup, which included subjects in whom no atherosclerotic changes 
had yet been initiated. 
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Conclusions: In T2DM patients without apparent arterial wall thickening, cystatin C is 
strongly and independently associated with arterial wall elasticity, which reflects the 
degree of subclinical atherosclerosis. Thus, cystatin C is a potentially useful marker of 
early-stage atherosclerosis. 
 
 
Keywords: early-stage atherosclerosis, cystatin C, arterial wall elasticity, type 2 
diabetes mellitus
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1. Introduction  
Type 2 diabetes mellitus (T2DM) is associated with atherosclerosis, which leads to 
cardiovascular disease and increased mortality [1]. However, it is difficult to detect 
atherosclerosis at its early stages. Arterial stenosis often develops without symptoms in 
T2DM patients [2], subsequently leading to cardiovascular events. Therefore, 
development of strategies for easily detecting early-stage atherosclerosis, such as 
identifying reliable biochemical markers, is particularly important in those with T2DM.  
Measurement of carotid intima-media thickness (IMT) is widely used for 
atherosclerosis screening in clinical practice but this examination detects morphological 
changes of atherosclerosis. For detecting early-stage atherosclerosis before the 
appearance of such morphological changes, we developed a novel non-invasive 
ultrasonic phased tracking method, which evaluates deformity at multiple sites in 
arterial walls during one heartbeat [3-6]. Since the arterial wall deforms less easily at 
harder sites during a single heartbeat, this innovative phased tracking method has 
enabled us to quantitatively analyze arterial wall elasticity. The results obtained with 
this method correspond to pathological findings in the extracted human iliac artery [5]. 
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In addition, we reported that phased tracking arterial wall elasticity, but not IMT, pulse 
wave velocity (PWV) or the plaque score, is associated with an increasing number of 
coronary risk factors such as diabetes, hypertension, hyperlipidemia and current 
smoking, in T2DM patients with IMT < 1.1 mm [7], who were classified as not having 
atherosclerosis according to the IMT criteria [8]. The elasticity in the carotid artery wall 
is also associated with visceral fat mass in subjects with obesity [9] and an increasing 
number of coronary risk factors in T2DM patients who have not developed apparent 
cardiovascular disease [10]. Furthermore, arterial wall elasticity is reportedly increased 
in smokers, as compared with non-smokers [11], and in subjects with the metabolic 
syndrome, as compared with those without metabolic syndrome [12], among subjects 
with IMT < 1.1 mm. Collectively, these findings indicate that arterial wall elasticity is 
useful for detecting early-stage atherosclerosis, i.e. that developing before IMT 
increases detectably. Therefore, in order to search for biochemical markers of 
early-stage atherosclerosis, we sought serum markers which have a strong association 
with arterial wall elasticity values.  
In the present study, we focused on serum cystatin C. Cystatin C, a 13-kD 
endogenous cysteine proteinase inhibitor, is considered to be a more reliable marker for 
glomerular filtration rates than estimated glomerular filtration rate (eGFR) [13]. 
5 
 
Moreover, cystatin C was reported to be associated with plaque morphology using 
multi-detector computed tomography [14] and coronary angiography [15], even in 
patients without established chronic kidney disease. Furthermore, Wang et al. 
demonstrated cystatin C, but not eGFR, to be associated with the presence of 
cardiovascular disease in subjects with mild renal impairment [16]. Similar findings, 
indicating that cystatin C is superior to eGFR for predicting cardiovascular events, were 
also reported in subjects with diabetes [17] as well as those with [18] and without [19] 
cardiovascular disease. Thus, cystatin C is not simply regarded as a marker of impaired 
kidney function but also as one which reflects cardiovascular disease due to advanced 
atherosclerosis. However, the association of cystatin C and early-stage atherosclerosis 
remains unclear.   
Herein, to assess whether the serum cystatin C level is linked to, and useful for 
detecting, early-stage atherosclerosis, we enrolled T2DM patients who had IMT of less 
than 1.1mm, the cut-off value for a plaque lesion, and analyzed the associations of 
cystatin C with examinations for assessing atherosclerosis, such as Eθ (an indicator of 
arterial wall elasticity) as well as IMT and the cardio-ankle vascular index (CAVI). We 
also compared the utility of cystatin C as an early-stage atherosclerosis marker with 
those of other renal markers, such as eGFR and urinary albumin excretion. 
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2. Materials and methods 
2.1. Study subjects 
This was a cross-sectional study consisting of 180 subjects with T2DM. The subjects 
were recruited from patients with T2DM admitted to the Department of Metabolism and 
Diabetes, Tohoku University Hospital for glycemic control during the period from 
January 2012 to December 2015. T2DM was defined according to the World Health 
Organization (WHO) criteria, or treatment for diabetes mellitus. The exclusion criteria 
for the enrollment in this study were pregnancy, thyroid disease, tumor and severe 
inflammation, because these conditions are known to affect cystatin C levels. Subjects 
with atrial fibrillation were also excluded because the intima media complex (IMC) 
during one heart beat was used for calculating Eθ. Since this study aimed to evaluate 
renal markers in early-stage atherosclerosis, subjects with IMT ≥ 1.1 mm, were also 
excluded. The study protocol was approved by the Tohoku University Institutional 
Review Board, in accordance with the World Medical Association Declaration of 
Helsinki. Written informed consent was obtained from each patient.  
We used the following criteria for cardiovascular risk factors. Hyperlipidemia was 
defined as total cholesterol ≥ 5.7 mmol/l (220 mg/dl) and/or triglycerides ≥ 1.7 mmol/l 
(150 mg/dl), based on the definition proposed by the Japan Atherosclerosis Society in 
7 
 
2007, or taking antihyperlipidemic drugs. The subjects whose systolic blood pressure ≥ 
140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, based on the definition 
proposed by the Japanese Society of Hypertension, or taking antihypertensive drugs 
were defined as having hypertension. The subjects who currently smoked were 
classified as current smokers. 
 
2.2. Measurement of Eθ 
Eθ in the carotid artery was evaluated using the phased tracking method. The arteries 
were scanned with ultrasonic diagnostic equipment (FUJIFILM FAZONE M) and a 
linear type probe with a frequency range of 5 to 10 MHz (FUJIFILM FZT L10-5 probe) 
in the supine position. By B-mode ultrasound, the IMC was longitudinally scanned at 
two points on the far wall of the common carotid artery, 1 cm and 3 cm proximal to the 
bifurcation. The portion of the IMC including plaques was excluded. The plaque was 
defined as a focal raised lesion, using an IMT cut-off value of 1.1 mm [8]. The 
quadrature demodulated signals of the IMC during 8 heartbeats were obtained with a 
high frame rate of 200 Hz. From these 8 heartbeats, we selected one heartbeat which 
yielded the most precise image. The sampling interval of the quadrature demodulated 
signal and the pitch of scan lines were 0.035 and 0.12 mm, respectively. The quadrature 
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demodulated signals were saved as raw data to a personal computer. A single 
well-trained sonographer (N.T.), who was unaware of the clinical characteristics of the 
subjects, analyzed the raw data to introduce Eθ based on the principal described 
previously [20] (Supplementary Fig. 1). Multiple points were preset from the luminal 
surface to the adventitia along each beam. Then, the displacement of each point during 
one heartbeat was obtained by applying the phased tracking method [3-6]. Er, which is 
the elastic modulus in the radial direction of each of the sampled points, was calculated 
using the following equation: Er = ΔP/ε, where ε = Δh/h0, and Δh is the maximum 
decrease in the thickness of the arterial wall during one heartbeat. ΔP is the pulse 
pressure, defined as the difference between systolic and diastolic brachial blood 
pressure. The h0 and r0 variables are the initial thickness and radius of the vessel at 
end-diastole, respectively. Eθ, which is the elastic modulus in the circumferential 
direction was calculated using the following equation: Eθ = (3/8) × (2r0/h0 + 1) × Er. 
The intraobserver coefficient of variation for Eθ was 7.0%.  
Due to the absence of normative data for Eθ, we referred to the Eθ values from the 
data of a healthy population from another cohort. The Sendai knowledge cluster 
initiative organized by the Ministry of Education, Culture, Sports, Science and 
Technology, Japan, performed population-based health care examinations including the 
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determination of Eθ in the carotid artery. After excluding hypertension, hyperlipidemia, 
and diabetes mellitus, 156 cases were defined as healthy subjects. Their mean age was 
47.7 ± 10.3 years and Eθ was 228.3 ± 72.0 kPa (unpublished data). 
 
2.3. Measurement of IMT 
IMT of the common carotid artery was measured employing the same scanning image, 
as that mentioned above for the measurement of Eθ. IMT was measured at a point on 
the far wall of the common carotid artery, in a 1 cm segment proximal to the bifurcation 
in a region free of plaque [21]. The mean value of the bilateral measurements was used 
for the analysis. The intraobserver coefficient of variation for IMT was 8.3%. 
 
2.4. Measurement of CAVI 
CAVI was measured using a pulse wave analytical instrument (VaSera; Fukuda Denshi, 
Tokyo, Japan) as described previously [22]. After a 10 min rest, cuffs were applied to 
the bilateral upper arms and ankles to detect each of the pulse waves. 
Electrocardiograph, phonocardiograph, and blood pressures were measured. CAVI was 
calculated using a conventional PWV measurement with the formula: CAVI = 
a{(2ρ/ΔP) × ln(Ps/Pd)PWV2} + b, where Ps is systolic blood pressure, Pd is diastolic 
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blood pressure, PWV is pulse wave velocity, ΔP is Ps - Pd, ρ is blood density, and a and 
b are both constant.  
 
2.5. Biochemical markers of renal function 
The eGFR was calculated using the formula recommended by the Japanese Society of 
Nephrology [23], derived from the Modification of Diet in Renal Disease (MDRD) 
study group. The urinary albumin excretion is presented as the albumin-to-creatinine 
ratio (ACR; mg/g creatinine). Cystatin C was assayed using colloidal gold 
immunoassay (Nescaute GC cystatin C; Alfresa Pharma, Osaka, Japan). 
 
2.6. Statistical analysis 
Continuous variables were expressed as means ± S.D. or medians (inter-quantile range 
(IQR)). The difference between 2 groups was determined using the unpaired t-test for 
continuous variables and Fisher’s exact test for non-continuous variables. Data were 
logarithmically transformed before statistical analysis if they were not normally 
distributed. Pearson correlation was used for correlation analysis. Multiple linear 
regression analysis was performed to evaluate the independent parameters that were 
found to be significantly related to the objective variable. The independent parameters 
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tested were age, male, systolic blood pressure, dyslipidemia, HbA1c, BMI, duration of 
diabetes, insulin, RAS inhibitors, calcium channel blocker, other agents for 
hypertension, statin, fibrate, other agents for dyslipidemia, insulin, GLP-1 receptor 
antagonist, other agents for diabetes, eGFR, cystatin C and log ACR. Among these 
variables, extreme collinearities were not found. Receiver-operating characteristic 
(ROC) curves for cystatin C was generated to determine optimal cut-off for high 
elasticity of arterial wall. We computed the sensitivity and specificity for high elasticity 
of arterial wall using this cut-off value for cystatin C. As for sample size calculation, we 
estimated the correlation coefficient of cystatin C and Eθ is estimated 0.25 from our 
preliminary study. We calculated 164 patients at a significance level α = 0.05, with 
power of 90%. The number of required patients was set at 180. A level of p < 0.05 was 
considered to indicate a statistically significant association. Analyses were carried out 
with JMP 11.2 Pro statistical analysis software (SAS Institute, Cavy, NC, USA). 
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3. Results 
3.1. Subject characteristics 
All 180 diabetic subjects enrolled in this study had IMT of less than 1.1 mm, the cut-off 
value for detecting atherosclerosis with this examination. The clinical characteristics of 
these subjects are shown in Table 1. Overall, 56.7% of the subjects were male, mean 
age was 52.0 ± 15.6 years, the diabetes duration was 8.0 (3.0-15.0) years, BMI was 27.3 
± 6.2 kg/m2, 64.4% of the subjects had hypertension, 70.0% had dyslipidemia, and 
11.7% had a history of cardiovascular disease. (reviwer#3 への返答) 
 
3.2. Associations of Eθ with cardiovascular risk factors  
We first assessed the associations of Eθ with cardiovascular risk factors. Eθ was 
significantly associated with age (r = 0.35, p < 0.01), BMI (r = -0.17, p = 0.02), systolic 
blood pressure (r = 0.35, p < 0.01), HbA1c (r = -0.19, p < 0.05), eGFR (r = -0.36, p < 
0.01) and serum cystatin C (r = 0.42, p < 0.01) (Table 2). We then focused on the 
associations of Eθ with renal markers such as eGFR, cystatin C and ACR levels. Eθ was 
significantly associated with eGFR (r = -0.36, p < 0.01) and cystatin C (r = 0.42, p < 
0.01), but not with ACR (r = 0.05, p = 0.48) (Supplementary Fig. 2A, B, C). Next, the 
subjects were divided into two groups by eGFR = 60 mL/min/1.73 m2, cystatin C = 0.95 
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mg/l and ACR = 30 mg/g creatinine. Subjects with eGFR < 60 had significantly higher 
Eθ than those with eGFR ≥ 60, and subjects with cystatin C ≥ 0.95 had significantly 
higher Eθ than those with cystatin C < 0.95. In contrast, subjects with ACR ≥ 30 had Eθ 
values similar to those with ACR < 30 (Supplementary Fig. 3A, B, C).  
Next, to identify the independent variables affecting Eθ, we performed multiple 
regression analysis. Seven clinical parameters, such as age, gender, systolic blood 
pressure, dyslipidemia, body mass index, HbA1c, duration of diabetes, use of 
medications, and each of the renal markers were included in the regression models. 
Cystatin C, eGFR and ACR were employed in models 1, 2 and 3, respectively. This 
analysis revealed that cystatin C (β = 0.29, p < 0.01), but neither eGFR (β = -0.15 p = 
0.09) nor ACR (β = -0.01, p = 0.88), was independently associated with Eθ in T2DM 
patients with IMT < 1.1 mm (Table 3). Thus, in T2DM subjects with IMT of less than 
1.1 mm, serum cystatin C is strongly and independently associated with arterial wall 
elasticity which reflects the degree of atherosclerosis in its early stages. 
 
3.3. Associations of cystatin C with Eθ, IMT, and CAVI 
To determine which of the atherosclerosis examinations, Eθ, IMT or CAVI, is most 
strongly associated with cystatin C, we next analyzed the results employing a different 
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approach. First, simple correlation analysis revealed that Eθ (r = 0.42, p < 0.01) and 
CAVI (r = 0.26, p < 0.01) were significantly associated with cystatin C, while IMT was 
not (Supplementary Fig. 4A, B, C). In addition, multiple regression analysis showed 
Eθ alone to be associated with cystatin C (β = 0.29, p < 0.01) independently of age, 
gender, systolic blood pressure, dyslipidemia, body mass index, HbA1c, duration of 
diabetes, use of medications, while neither IMT (β = -0.04, p = 0.66) nor CAVI (β = 
0.05, p = 0.45) showed association (Table 4). These results indicate that cystatin C is 
strongly associated with arterial wall elasticity, i.e. Eθ, which is the most sensitive 
examination of the three for early-stage atherosclerosis. Collectively, these observations 
suggest the serum cystatin C level to be a highly sensitive marker for early-stage 
atherosclerosis. 
 
3.4. Subgroup analysis based on low and high Eθ 
Finally, we investigated whether cystatin C is associated with early-stage atherosclerosis, 
i.e., whether the cystatin C association with Eθ values is less significant in subjects who 
have not yet developed atherosclerosis. All 180 diabetic subjects with IMT of less than 
1.1 mm were divided into two groups using the median Eθ value (243 kPa) as the 
cut-off. In the low Eθ group, mean Eθ was 197.0 ± 31.2 kPa (Table 1). In comparison to 
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the Eθ values of the aforementioned healthy population (228.3±72.0 kPa), we assumed 
that there would be essentially no atherosclerosis, even in the early stage, in subjects in 
the low Eθ group. In contrast, subjects in the high Eθ group (321.3 ± 69.2 kPa) would 
be likely to have early-stage atherosclerosis not yet detectable as IMT change but with 
higher than average Eθ. Consistent with this assumption, age, duration of diabetes, 
systolic blood pressure, cystatin C and CAVI values were significantly higher in the 
high Eθ group (Table 1). Eθ showed a weak correlation with eGFR in the low Eθ group 
(r = -0.21, p < 0.05), while Eθ showed a modest correlation with eGFR in the high Eθ 
group (r = -0.39, p < 0.01) (Supplementary Fig. 2D, G). Interestingly, Eθ showed a 
strong correlation with cystatin C in the high Eθ group (r = 0.56, p < 0.01), while no 
significant difference was detected in the low Eθ group (r = 0.05 p = 0.67). 
(Supplementary Fig. 2E, H). The subjects with eGFR < 60 had significantly higher Eθ 
than those with eGFR ≥ 60 in the high Eθ group (Supplementary Fig. 3G). 
Additionally, subjects with cystatin C ≥ 0.95 had significantly higher Eθ than those with 
cystatin C < 0.95 in the high Eθ group (Supplementary Fig. 3H). However, there were 
no differences in Eθ between any two groups according to the renal markers in the low 
Eθ group (Supplementary Fig. 3D, E, F). In addition, multiple regression analysis 
demonstrated that cystatin C was associated with Eθ in the high Eθ group independently 
16 
 
of age, gender, systolic blood pressure, dyslipidemia, body mass index and HbA1c, 
duration of diabetes, use of medications (β = 0.51, p < 0.01), while no significant 
association was observed in the low Eθ group (Table 5). This subgroup analysis showed 
the association between cystatin C and Eθ to be even stronger in the high Eθ group than 
in the low Eθ group. Thus, cystatin C was not associated with arterial wall elasticity in 
subjects in whom no atherosclerotic changes had yet been initiated (IMT < 1.1 mm and 
Eθ < 243 kPa). In contrast, cystatin C very sensitively reflects the degree of 
atherosclerotic change in the early stage, as indicated by increased arterial elasticity 
(IMT < 1.1 mm and Eθ ≥ 243 kPa). Finally, ROC curves for cystatin C was generated to 
determine optimal cut-off for high elasticity of arterial wall (Supplementary Fig. 5). 
The area under the curve was 0.59, and the sensitivity and specificity were 0.66 and 
0.49, respectively, at cystatin C = 0.86 mg/l.    
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4. Discussion 
In the present study, to examine whether the serum cystatin C level is linked to 
early-stage atherosclerosis, we analyzed the associations between renal markers and 
atherosclerosis markers in T2DM patients with IMT of less than 1.1 mm, who are 
classified as not having atherosclerosis according to the IMT criteria [8]. In these 
subjects, multiple regression analyses revealed cystatin C to be strongly and 
independently associated with Eθ, while neither eGFR nor ACR showed a significant 
association. In addition, Eθ was the more strongly associated with cystatin C than either 
IMT or CAVI. These findings demonstrate that serum cystatin C levels reflect the 
degrees of atherosclerosis before arterial wall thickening becomes detectable.  
Furthermore, the association between cystatin C and Eθ was more evident in the high 
Eθ subgroup. In contrast, the significance of this association disappeared in the low Eθ 
subgroup. Eθ values in the low Eθ subgroup were significantly smaller than those in a 
healthy population. Considering that all of the enrolled subjects had IMT of less than 
1.1 mm, the subjects in the low Eθ subgroup presumably had normal arterial structure 
and stiffness. Therefore, these findings indicate that the association between cystatin C 
and Eθ manifests after atherosclerotic changes have been initiated. Thus, the serum 
cystatin C level is likely to be useful as a marker for screening early-stage 
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atherosclerosis, i.e. that after increased elasticity has been initiated but before arterial 
wall thickening becomes apparent. Moreover, in our study, the optimal cut-off values of 
cystatin C for predicting high arterial wall elasticity was 0.86 mg/l. We may consider 
the diabetic patients with cystatin C > 0.86 mg/l, even not having cardiovascular disease, 
initiate an early atherosclerosis in clinical practice. 
T2DM is well known to be associated with atherosclerosis, which leads to 
cardiovascular disease and increasing mortality rates [1]. In patients with T2DM 
especially, arterial stenosis often develops without symptoms [2]. According to a 
meta-analysis of prospective studies, 26.1% of asymptomatic T2DM patients have silent 
myocardial ischemia based on screening by myocardial perfusion scintigraphy [24]. 
Therefore, to reduce the risk of future cardiovascular disease in patients with T2DM, 
detection of subclinical atherosclerosis is particularly important. Conventional 
angiography, computed tomography and magnetic resonance angiography are often used 
to diagnose atherosclerosis in clinical practice. However, these modalities are useful for 
detecting advanced, rather than early-stage, atherosclerosis. Our phased tracking method, 
which evaluates the deformities of multiple sites in arterial walls during one heartbeat, 
is useful for detecting early-stage atherosclerosis [3-6]. Employing the results obtained 
with the phased tracking method, the elastic modulus in the radial direction (Er) and that 
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in the circumferential direction (Eθ) are quantitatively calculated. We and other groups 
previously reported these elastic modulus values to be more reliable and useful for 
detecting early-stage atherosclerosis than examining carotid IMT, PWV and the plaque 
score of the carotid artery, all of which are widely used for atherosclerosis screening in 
clinical practice [7, 9-12]. When considering Er and Eθ, the latter appears to be a more 
reliable marker for arterial wall elasticity, since Eθ is less influenced by the thickness of 
the arterial wall [3]. Therefore, we measured the elastic modulus, Eθ, in the present 
study. We obtained results indicating the serum cystatin C level to be strongly 
associated with Eθ in T2DM patients with IMT < 1.1 mm. This association was 
independent of age, gender, systolic blood pressure, dyslipidemia, body mass index, 
HbA1c, duration of diabetes, and use of medications. Thus, the phased tracking method 
enabled us to show that the serum cystatin C level is associated with atherosclerosis 
development at an early stage, i.e. before arterial wall thickening becomes apparent.  
Carotid arterial IMT is a well-established surrogate marker for cardiovascular disease. 
Measuring IMT with ultrasonography is non-invasive, reproducible and easy to perform, 
and, therefore, is widely used in clinical practice. A number of studies have shown that 
IMT predicts future myocardial infarction [25, 26] and cerebrovascular disease [26, 27]. 
However, employing this procedure, it is not possible to make a diagnosis of 
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atherosclerosis until the appearance of arterial wall thickening. Therefore, IMT 
measurement is not optimal for sensitively detecting early-stage atherosclerosis. Indeed, 
the significance of carotid IMT in addition to conventional coronary risk factors for 
predicting future cardiovascular events remains a matter of debate [28, 29]. In the 
present study, we enrolled T2DM patients with IMT of less than 1.1 mm, who are 
classified as not having atherosclerosis according to the IMT criteria [8]. Within this 
IMT range, there was no significant association between cystatin C and IMT. 
Cystatin C may provide a more sensitive and accurate estimation of renal function 
than eGFR, since cystatin C is less influenced by age and muscle mass [13]. We 
obtained data indicating the serum cystatin C level to be strongly associated with Eθ, a 
sensitive marker of early-stage atherosclerosis, while neither eGFR nor ACR was 
associated with Eθ, In addition, Eθ was more strongly associated with cystatin C than 
was either IMT or CAVI. Furthermore, multiple regression analysis revealed a strong 
relationship between cystatin C and Eθ, especially in the subgroup with relatively high 
arterial wall elasticity. One possible explanation of these results is that renal impairment 
is associated with atherosclerosis development starting in the very early stages of both 
disorders. On the other hand, it is also possible that cystatin C might itself be directly 
involved in the development of atherosclerosis [30]. Cystatin C is an endogenous 
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inhibitor of cysteine protease. Atherosclerosis is an inflammatory disease characterized 
by remodeling of the extracellular matrix of the arterial walls and cysteine protease 
induces degradation of the extracellular matrix. The imbalance between cysteine 
protease and its inhibitor, cystatin C, may result in increased degradation of 
extracellular matrix and migration of monocytes/macrophages into the intima, thus 
leading to the development of atherosclerosis. Tissue cystatin C levels are reportedly 
reduced in atherosclerotic plaques [31]. In contrast, inflammatory cytokines stimulate 
cells outside of the vascular walls to secrete cystatin C into the circulation. Thus, serum 
cystatin C is considered to be compensatorily up-regulated in subjects who have 
developed atherosclerosis [32]. Although further studies are needed to examine whether 
this mechanism also accounts for serum cystatin C levels rising in states of subclinical 
atherosclerosis, as found in this study, the serum cystatin C level is likely to reflect the 
degree of the atherosclerotic states via mechanisms both dependent on, and independent 
of, glomerular filtration rates. 
This study has limitations. First, the possible causal relationship between cystatin C 
and Eθ could not be clarified due to the cross-sectional study design. Second, although 
we adjusted for well-known confounders such as age, gender, blood pressure, 
dyslipidemia, body mass index, and HbA1c, duration of diabetes, use of medications. 
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However, residual confounding may have occurred. Third, our patients were recruited in 
a hospital setting after admission for poor glycemic control, then bias of recruitment 
may exist. In fact, average HbA1c of our patients was 10.0%, which is extremely high. 
Moreover, because blood drawings were performed one day after the admission, fasting 
plasma glucose may be improved owing to dietary treatment in hospital. Then, fasting 
plasma glucose may not reflect HbA1c. Forth, there are few evidence that demonstrated 
that carotid arterial wall elasticity by phased tracking method is a good surrogate marker 
of atherosclerosis, especially in patients without morphological changes in arterial wall 
thickness [7, 12]. Further research are needed to confirm the results of our study. Fifth, 
all of the subjects had T2DM and the lack of age- and gender-matched healthy controls 
limits the generalizability of our findings. Further studies, especially larger, 
population-based prospective studies, are needed to overcome these limitations. 
In conclusion, our results indicate that the serum cystatin C level is associated with 
arterial wall elasticity, a sensitive examination for early-stage atherosclerosis, in 
subjects classified as not having atherosclerosis as defined by IMT criteria. Thus, the 
serum cystatin C level may reflect the degrees of atherosclerotic changes in the early 
stages of this disorder. Measuring the serum cystatin C level appears to be useful for 
detecting subclinical atherosclerosis in subjects with T2DM.  
23 
 
 
Funding sources 
This work was supported by Grants-in-Aid for Scientific Research (16K09773 and 
15K09416) to S. Sawada and Y. Ishigaki, respectively, from Japan Society for the 
Promotion of Science. 
 
Conflicts of interests 
The authors declare that they have no competing interests. 
 
Author contributions 
R.K. conceived the hypothesis, performed the experiments, and analyzed the data. S.S. 
A.T, R.H. and Y.I performed the experiments. S.K., T.I., K.T., K.U., J.I. and T.Y 
contributed to discussions and recruitment of patients. Y.M., H.H. and H.K. provided 
technical advice on the ultrasonic equipment. N.T. provided ultrasonic analysis of 
arterial wall elasticity. H.K. directed the project, and prepared the manuscript.  
  
24 
 
References 
[1] Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. 
Jama. 1979;241(19):2035-8. 
[2] Nesto RW, Phillips RT. Asymptomatic myocardial ischemia in diabetic patients. The 
American journal of medicine. 1986;80(4c):40-7. 
[3] Hasegawa H, Kanai H, Hoshimiya N, Koiwa Y. Evaluating the regional elastic modulus 
of a cylindrical shell with nonuniform wall thickness. Journal of medical ultrasonics (2001). 
2004;31(2):81-90. 
[4] Hasegawa H, Kanai H, Ichiki M, Tezuka F. Tissue structure of arterial wall revealed with 
elasticity imaging. Journal of medical ultrasonics (2001). 2007;34(1):73-4. 
[5] Kanai H, Hasegawa H, Ichiki M, Tezuka F, Koiwa Y. Elasticity imaging of atheroma with 
transcutaneous ultrasound: preliminary study. Circulation. 2003;107(24):3018-21. 
[6] Kanai H, Koiwa Y, Zhang J. Real-time measurements of local myocardium motion and 
arterial wall thickening. IEEE Trans Ultrason Ferroelectr Freq Control. 1999;46(5):1229-41. 
[7] Okimoto H, Ishigaki Y, Koiwa Y, Hinokio Y, Ogihara T, Suzuki S, et al. A novel method for 
evaluating human carotid artery elasticity: possible detection of early stage atherosclerosis 
in subjects with type 2 diabetes. Atherosclerosis. 2008;196(1):391-7. 
[8] Katakami N, Kaneto H, Shimomura I. Carotid ultrasonography: A potent tool for better 
clinical practice in diagnosis of atherosclerosis in diabetic patients. Journal of diabetes 
investigation. 2014;5(1):3-13. 
[9] Tokita A, Ishigaki Y, Okimoto H, Hasegawa H, Koiwa Y, Kato M, et al. Carotid arterial 
elasticity is a sensitive atherosclerosis value reflecting visceral fat accumulation in obese 
subjects. Atherosclerosis. 2009;206(1):168-72. 
[10] Miyamoto M, Kotani K, Okada K, Ando A, Hasegawa H, Kanai H, et al. Arterial wall 
elasticity measured using the phased tracking method and atherosclerotic risk factors in 
patients with type 2 diabetes. Journal of atherosclerosis and thrombosis. 2013;20(8):678-87. 
[11] Yamagishi T, Kato M, Koiwa Y, Hasegawa H, Kanai H. Usefulness of measurement of 
carotid arterial wall elasticity distribution in detection of early-stage atherosclerotic lesions 
caused by cigarette smoking. Journal of medical ultrasonics (2001). 2006;33(4):203-10. 
[12] Yamagishi T, Kato M, Koiwa Y, Hasegawa H, Kanai H. Impact of lifestyle-related 
diseases on carotid arterial wall elasticity as evaluated by an ultrasonic phased-tracking 
method in Japanese subjects. Journal of atherosclerosis and thrombosis. 2009;16(6):782-91. 
[13] Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. 
Estimating glomerular filtration rate from serum creatinine and cystatin C. The New 
England journal of medicine. 2012;367(1):20-9. 
25 
 
[14] Imai A, Komatsu S, Ohara T, Kamata T, Yoshida J, Miyaji K, et al. Serum cystatin C is 
associated with early stage coronary atherosclerotic plaque morphology on multidetector 
computed tomography. Atherosclerosis. 2011;218(2):350-5. 
[15] Batra A, Kapoor A, Sharma RK, Agrawal N, Sinha A, Kumar S, et al. Association of 
plasma cystatin C levels with angiographically documented coronary artery disease in 
patients of Indian origin. Journal of cardiology. 2012;59(2):182-9. 
[16] Wang J, Sim AS, Wang XL, Salonikas C, Moriatis M, Naidoo D, et al. Relations between 
markers of renal function, coronary risk factors and the occurrence and severity of coronary 
artery disease. Atherosclerosis. 2008;197(2):853-9. 
[17] Schottker B, Herder C, Muller H, Brenner H, Rothenbacher D. Clinical utility of 
creatinine- and cystatin C-based definition of renal function for risk prediction of primary 
cardiovascular events in patients with diabetes. Diabetes care. 2012;35(4):879-86. 
[18] Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin 
C in patients with coronary heart disease and risk for secondary cardiovascular events: 
more than simply a marker of glomerular filtration rate. Clinical chemistry. 
2005;51(2):321-7. 
[19] Luc G, Bard JM, Lesueur C, Arveiler D, Evans A, Amouyel P, et al. Plasma cystatin-C 
and development of coronary heart disease: The PRIME Study. Atherosclerosis. 
2006;185(2):375-80. 
[20] Yukiya M, Hideyuki H, Hiroshi K. Automated detection of arterial wall boundaries 
based on correlation between adjacent receive scan lines for elasticity imaging. Japanese 
Journal of Applied Physics. 2015;54(7S1):07HF18. 
[21] Sidhu PS, Desai SR. A simple and reproducible method for assessing intimal-medial 
thickness of the common carotid artery. The British journal of radiology. 1997;70:85-9. 
[22] Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial 
wall stiffness parameter; cardio-ankle vascular index (CAVI). Journal of atherosclerosis and 
thrombosis. 2006;13(2):101-7. 
[23] Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for 
estimated GFR from serum creatinine in Japan. American journal of kidney diseases : the 
official journal of the National Kidney Foundation. 2009;53(6):982-92. 
[24] Zhang L, Li H, Zhang S, Jaacks LM, Li Y, Ji L. Silent myocardial ischemia detected by 
single photon emission computed tomography (SPECT) and risk of cardiac events among 
asymptomatic patients with type 2 diabetes: a meta-analysis of prospective studies. Journal 
of diabetes and its complications. 2014;28(3):413-8. 
[25] Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid 
intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. 
26 
 
Circulation. 1997;96(5):1432-7. 
[26] O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. 
Carotid-artery intima and media thickness as a risk factor for myocardial infarction and 
stroke in older adults. Cardiovascular Health Study Collaborative Research Group. The 
New England journal of medicine. 1999;340(1):14-22. 
[27] Touboul PJ, Elbaz A, Koller C, Lucas C, Adrai V, Chedru F, et al. Common carotid artery 
intima-media thickness and brain infarction : the Etude du Profil Genetique de l'Infarctus 
Cerebral (GENIC) case-control study. The GENIC Investigators. Circulation. 
2000;102(3):313-8. 
[28] del Sol AI, Moons KG, Hollander M, Hofman A, Koudstaal PJ, Grobbee DE, et al. Is 
carotid intima-media thickness useful in cardiovascular disease risk assessment? The 
Rotterdam Study. Stroke; a journal of cerebral circulation. 2001;32(7):1532-8. 
[29] Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, et al. Carotid intima-media 
thickness and presence or absence of plaque improves prediction of coronary heart disease 
risk: the ARIC (Atherosclerosis Risk In Communities) study. Journal of the American 
College of Cardiology. 2010;55(15):1600-7. 
[30] Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. 
Annual review of physiology. 1997;59:63-88. 
[31] Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, et al. Cystatin C 
deficiency in human atherosclerosis and aortic aneurysms. The Journal of clinical 
investigation. 1999;104(9):1191-7. 
[32] Salgado JV, Souza FL, Salgado BJ. How to understand the association between cystatin 
C levels and cardiovascular disease: Imbalance, counterbalance, or consequence? Journal of 
cardiology. 2013;62(6):331-5. 
 
  
27 
 
Table 1 
Subject characteristics 
 All subjects (n=180) Low Eθ (n=90) High Eθ (n=90) p 
Male gender (%) 56.7 50.0 63.3 0.10 
Age (years) 52.0 ± 15.6 48.0 ± 15.1 55.4 ± 15.3 < 0.01 
Duration of diabetes (years) 8.0 (3.0-15.0) 6.0 (2.0-13.0) 10.0 (4.0-20.0) < 0.01 
Body mass index (kg/m2) 27.3 ± 6.2 27.9 ± 6.0 26.7 ± 6.3 0.21 
Systolic blood pressure (mmHg) 118.3 ± 15.7 114.8 ± 13.4 121.8 ± 17.0 < 0.01 
Diastolic blood pressure (mmHg) 73.5 ± 11.5 74.0 ± 9.8 72.9 ± 13.0 0.53 
Fasting plasma glucose (mg/dl) 151.8 ± 54.1 157.0 ± 58.5 146.3 ± 48.9 0.17 
HbA1c (%) 10.0 ± 2.0 10.3 ± 2.1 9.7 ± 1.9 < 0.05 
Total cholesterol (mg/dl) 182.8 ± 41.6 188.6 ± 41.8 177.0 ± 40.8 0.06 
Triglyceride (mg/dl) 
131.5       
(93.0-175.3) 
132.5       
(94.8-193.3) 
131.5       
(90.5-160.3) 
0.91 
HDL cholesterol (mg/dl) 43.6 ± 12.6 43.7 ± 13.4 43.4 ± 11.8 0.89 
LDL cholesterol (mg/dl) 108.5 ± 35.6 115.0 ± 34.7 102.3 ± 35.5 < 0.05 
eGFR (ml/min/1.73m2) 85.9 ± 29.5 92.0 ± 26.8 79.9 ± 30.9 < 0.01 
Cystatin C (mg/l) 0.94 ± 0.30 0.89 ± 0.21 1.00 ± 0.37 < 0.05 
ACR (mg/g creatinine) 15.6 (6.3-52.3) 15.7 (6.4-38.0) 12.3 (6.3-54.7)  0.97 
Hypertension (%) 64.4 54.4 70.0 0.16 
Dyslipidemia (%) 70.0 68.9 71.1 0.87 
Current smokers (%) 35.8 38.6 33.0 0.53 
Eθ (kPa) 259.1 ± 82.1 197.0 ± 31.2 321.3 ± 69.2 < 0.01 
IMT (mm) 0.70 ± 0.16 0.69 ± 0.17 0.70 ± 0.15 0.81 
CAVI 7.9 ± 1.6 7.5 ± 1.6 8.4 ± 1.6 < 0.01 
RAS inhibitors (%) 55.6 52.2 58.9 0.45 
Calcium channel blocker (%) 33.3 23.3 43.3 < 0.01 
Other agents for hypertension (%) 16.1 8.9 23.3 < 0.05 
Statin (%) 45.6 41.1 50.0 0.29 
Fibrate (%) 3.9 2.2 5.6 0.44 
Other agents for dyslipidemia (%) 12.2 8.9 15.6 0.25 
Insulin (%) 57.2 52.2 62.2 0.23 
GLP-1 receptor antagonist (%) 7.2 5.6 8.9 0.57 
Other agents for diabetes (%) 80.0 80.0 80.0 1.00 
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Data are presented as means ± SD and or medians (inter-quantile range (IQR)) for 
continuous variables and % for categorical variables. p value for the comparison 
between low and high Eθ group. 
  
History of cardiovascular disease 
(%) 
11.7 6.7 16.7 0.06 
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Table 2 
Correlations of Eθ with cardiovascular risk factors in all subjects 
 
 r p 
Age (years) 0.35 < 0.01 
Body mass index (kg/m2) -0.17 0.02 
Systolic blood pressure (mmHg) 0.35 < 0.01 
Diastolic blood pressure (mmHg) -0.02 0.79 
Fasting blood glucose (mg/dl) -0.12 0.10 
HbA1c (%) -0.19 <0.05 
eGFR (ml/min/1.73m2) -0.36 < 0.01 
Cystatin C (mg/l) 0.42 < 0.01 
ACR (mg/g creatinine) a 0.05 0.48 
Dyslipidemia 0.02 0.80 
 
a Log transformed before analysis. 
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Table 3 
Multiple regression analysis of Eθ associations with cardiovascular risk factors in 
all subjects 
 
 Model 1 b Model 2 c Model 3 d 
 β p β p β p 
Age (years) 0.21 < 0.05 0.20 < 0.05 0.27 < 0.01 
Male gender 0.10 0.15 0.12 0.10 0.14 0.05 
Systolic blood pressure (mmHg) 0.33 < 0.01 0.33 < 0.01 0.34 < 0.01 
Dyslipidemia 0.01 0.95 0.02 0.85 0.00 0.97 
Body mass index (kg/m2) -0.24 < 0.01 -0.20 < 0.05 -0.19 < 0.05 
HbA1c (%) -0.12 0.09 -0.15 < 0.05 -0.16 < 0.05 
Duration of diabetes (years) -0.02 0.82 0.02 0.84 0.03 0.71 
RAS inhibitors (%) -0.14 0.07 -0.14 0.09 -0.12 0.13 
Calcium channel blocker (%) 0.05 0.55 0.04 0.62 0.05 0.60 
Other agents for hypertension (%) 0.00 0.98 0.05 0.51 0.07 0.41 
Statin (%) -0.02 0.79 -0.02 0.85 0.01 0.90 
Fibrate (%) 0.06 0.39 0.08 0.25 0.10 0.15 
Other agents for dyslipidemia (%) -0.05 0.48 -0.07 0.34 -0.06 0.40 
Insulin 0.10 0.16 0.13 0.10 0.11 0.14 
GLP-1 receptor antagonist (%) 0.22 < 0.01 0.21 < 0.01 0.21 < 0.01 
Other agents for diabetes (%) 0.05 0.52 0.03 0.71 0.01 0.87 
Cystatin C (mg/l) 0.29 < 0.01 - - - - 
eGFR (ml/min/1.73m2) - - -0.15 0.09 - - 
ACR (mg/g creatinine) a - - - - -0.01 0.88 
 
Multiple regression analysis was used to examine the relationships of Eθ (objective 
variable) with age, male gender, systolic blood pressure, dyslipidemia, body mass index, 
HbA1c, duration of diabetes, RAS inhibitor, calcium channel blocker, other agents for 
hypertension, statin, fibrate, other agents for dyslipidemia, insulin, GLP-1 receptor 
agonist, other agents for diabetes, and each renal marker (explanatory variables).  
a Log transformed before analysis. 
b R2 = 0.43, c R2 = 0.38, d R2 = 0.37. 
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Table 4 
Multiple regression analysis of Eθ, IMT and CAVI associations with 
cardiovascular risk factors 
 
 
 
Multiple regression analysis was used to examine the relationships of Eθ, IMT, and 
CAVI (objective variables) with age, male gender, systolic blood pressure, dyslipidemia, 
body mass index, HbA1c, duration of diabetes, RAS inhibitor, calcium channel blocker, 
other agents for hypertension, statin, fibrate, other agents for dyslipidemia, insulin, 
GLP-1 receptor agonist, other agents for diabetes, and cystatin C (explanatory 
variables). 
a R2 = 0.43, b R2 = 0.33, c R2 = 0.58. 
 
  
 Eθ a IMT b CAVI c 
β p β p β p 
Age (years) 0.21 < 0.05 0.56 < 0.01 0.54 < 0.01 
Male gender 0.10 0.15 0.15 < 0.05 0.19 < 0.01 
Systolic blood pressure (mmHg) 0.33 < 0.01 0.19 < 0.05 0.02 0.76 
Dyslipidemia 0.01 0.95 0.11 0.27 0.02 0.83 
Body mass index (kg/m2) -0.24 < 0.01 0.05 0.59 -0.19 < 0.01 
HbA1c (%) -0.12 0.09 0.15 < 0.05 -0.06 0.29 
Duration of diabetes (years) -0.02 0.82 -0.07 0.40 0.18 < 0.05 
RAS inhibitors (%) -0.14 0.07 0.07 0.39 0.10 0.15 
Calcium channel blocker (%) 0.05 0.55 -0.08 0.38 -0.08 0.27 
Other agents for hypertension (%) 0.00 0.98 -0.06 0.43 -0.14 < 0.05 
Statin (%) -0.02 0.79 0.02 0.85 0.08 0.29 
Fibrate (%) 0.06 0.39 0.03 0.64 0.03 0.58 
Other agents for dyslipidemia (%) -0.05 0.48 -0.03 0.70 0.03 0.62 
Insulin 0.10 0.16 0.02 0.83 -0.15 < 0.05 
GLP-1 receptor antagonist (%) 0.22 < 0.01 0.03 0.66 -0.04 0.54 
Other agents for diabetes (%) 0.05 0.52 0.05 0.54 -0.17 < 0.01 
Cystatin C (mg/l) 0.29 < 0.01 -0.04 0.66 0.05 0.45 
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Table 5 
Multiple regression analysis of Eθ associations with cardiovascular risk factors, in 
low and high Eθ subgroups 
 
 
Multiple regression analysis was used to examine the relationships of Eθ (objective 
variable) with age, male gender, systolic blood pressure, dyslipidemia, body mass index, 
HbA1c, duration of diabetes, RAS inhibitor, calcium channel blocker, other agents for 
hypertension, statin, fibrate, other agents for dyslipidemia, insulin, GLP-1 receptor 
agonist, other agents for diabetes, and cystatin C (explanatory variables). 
a R2 = 0.39, b R2 = 0.55. 
  
 Low Eθ (n = 90) a High Eθ (n = 90) b 
 β p β p 
Age (years) 0.29 < 0.05 0.07 0.58 
Male gender 0.10 0.36 -0.03 0.70 
Systolic blood pressure (mmHg) 0.25 < 0.05 0.37 < 0.01 
Dyslipidemia 0.21 0.14 0.07 0.63 
Body mass index (kg/m2) -0.29 < 0.05 -0.29 < 0.05 
HbA1c (%) -0.02 0.87 -0.13 0.17 
Duration of diabetes (years) -0.26 0.07 -0.03 0.76 
RAS inhibitors (%) 0.16 0.23 -0.05 0.66 
Calcium channel blocker (%) -0.09 0.50 -0.04 0.73 
Other agents for hypertension (%) -0.04 0.73 -0.02 0.86 
Statin (%) -0.21 0.15 -0.08 0.58 
Fibrate (%) 0.14 0.17 0.00 1.00 
Other agents for dyslipidemia (%) -0.33 < 0.01 -0.11 0.24 
Insulin 0.18 0.15 0.08 0.24 
GLP-1 receptor antagonist (%) 0.45 < 0.01 0.15 0.10 
Other agents for diabetes (%) 0.07 0.57 -0.09 0.40 
Cystatin C (mg/l) 0.03 0.84 0.51 < 0.01 
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Supplementary Fig. 1    
Evaluation of arterial wall elasticity by phase tracking method 
Elasticity image is displayed as 2D cross-sectional color image. Multiple sites are preset 
from the luminal surface to the adventitia (sampling pitch; 0.035 mm, line pitch; 0.12 
mm) and the elasticity in each module is measured by the phased tracking method. The 
change in thickness at each depth during one heartbeat are obtained simultaneously, and 
the elastic modulus in circumferential direction (Eθ) is calculated using the appropriate 
equations. 
 
Supplementary Fig. 2 
Association of Eθ with renal markers 
Associations of Eθ with eGFR (A), cystatin C (B) and log ACR (C) in all subjects. 
Associations of Eθ with eGFR (D), cystatin C (E) and log ACR (F) in the low Eθ 
subgroup. Association of Eθ with eGFR (G), cystatin C (H), and log ACR (I) in the high 
Eθ subgroup. 
eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio; Pa, 
Pascal. 
 
Supplementary Fig. 3 
Comparison of Eθ in pairs of study groups divided by renal markers in the 
subgroup analysis 
Comparison of Eθ in pairs of study groups divided by eGFR = 60 ml/min per 1.73 m2 
(A), cystatin C = 0.95 mg/l (B), and ACR = 30 mg/g creatinine (C) in all subjects. 
Comparison of Eθ in two study groups divided by eGFR = 60 ml/min per 1.73 m2 (D), 
35 
 
cystatin C = 0.95 mg/l (E), and ACR = 30 mg/g creatinine (F) in the low Eθ group. 
Comparison of Eθ in two study groups divided by eGFR = 60 ml/min per 1.73 m2 (G), 
cystatin C = 0.95 mg/l (H), and ACR = 30 mg/g creatinine (I) in the high Eθ group. 
eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio; Pa, 
Pascal. 
 
Supplementary Fig. 4 
Association of atherosclerotic markers with cystatin C  
Associations of Eθ (A), IMT (B) and CAVI (C) with cystatin C in all subjects.  
IMT, intima media thickness; CAVI, caridio-ankle velocity index; Pa, Pascal. 
 
Supplementary Fig. 5 
Receiver-operating characteristics curve of cystatin C for high elasticity of the 
arterial wall 
Receiver-operating characteristics curve of cystatin C for arterial wall elasticity defined 
as Eθ > 242kPa. Area under the curve was 0.593. The optimal cut-off for high elasticity 
of the arterial wall was 0.86 mg/l with sensitivity of 0.66 and specificity of 0.49. 
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